Axovant Sciences has reported negative top-line results from its Phase III MINDSET clinical trial of intepirdine conducted to treat mild-to-moderate Alzheimer’s disease (AD).

Intepirdine is an investigational, oral, once-daily 5-HT6 receptor antagonist being developed to release acetylcholine required for cognition and function in the brain.

The trial did not meet its co-primary efficacy endpoints and the results revealed that patients administered with 35mg of intepirdine did not achieve improved cognition at 24 weeks, compared to placebo.

Additionally, patients did not experience improvement in measures of daily activities analysed using Alzheimer’s disease assessment scale-cognitive subscale (ADAS-Cog) and Alzheimer’s disease cooperative study activities of daily living scale (ADCS-ADL).

The global, randomised, double-blind, placebo-controlled MINDSET trial assessed the safety, efficacy and tolerability of intepirdine in 1,315 patients who were on background donepezil therapy.

“While we are deeply disappointed by these trial results, we also are saddened for the millions of patients and families impacted by Alzheimer’s disease.”

Axovant CEO David Hung said: “While we are deeply disappointed by these trial results, we also are saddened for the millions of patients and families impacted by Alzheimer’s disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“However, we believe that the fight against Alzheimer’s and other important areas of unmet need in neurology is too important to be derailed by this setback.”

In the Phase III trial, intepirdine was observed to be generally well tolerated and achieved significant improvement in only one key secondary endpoint; the clinician interview-based impression of change.

The firm intends to continue evaluation of intepirdine in the Phase IIb HEADWAY trial being performed in dementia patients with Lewy bodies (DLB).

Expected to report top-line data by the end of this year, the Phase IIb trial is investigating 35mg of intepirdine, along with its 70mg dose to target both 5-HT6 and 5-HT2A receptors.